Widdrol is a sesquiterpene alcohol most strongly associated with cedarwood-type oils, especially Virginian and Texas cedarwood profiles where it recurs as a smaller but characteristic oxygenated constituent. Compared with many wood-oil markers, widdrol has a modest standalone preclinical literature covering antifungal testing, cancer-cell cycle work, and anti-angiogenic signaling. Those findings remain experimental, so AromaForge should position widdrol as a cedarwood chemistry marker with mechanism-rich lab data and limited direct human safety evidence.
Chemical identity and composition
PubChem lists widdrol as CID 94334 with formula C15H26O and IUPAC name (7S,9aS)-4,4,7,9a-tetramethyl-1,2,3,6,8,9-hexahydrobenzo[7]annulen-7-ol. PubChem synonym data supports CAS 6892-80-4, which is more consistent with live chemistry databases than the conflicting CAS values present in some local oil files. NTP's cedarwood-oil introduction notes that ISO chromatographic standards for Juniperus virginiana cedarwood include widdrol at 2% to 5%, matching its role in AromaForge cedarwood records.
Aroma and practical use
- Use the recorded cedarwood, woody, dry, balsamic, cedar-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
NTP's cedarwood-oil introduction states that ISO standards for Juniperus virginiana cedarwood set widdrol in a 2% to 5% chromatographic range.
This is high-value identity context because it confirms widdrol as a standardized cedarwood marker rather than an incidental occurrence.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2010 Cancer Letters paper reported that widdrol induced cell-cycle arrest associated with MCM down-regulation in human colon adenocarcinoma cells.
This is one of the earliest direct isolated-compound anticancer-mechanism signals in the widdrol literature, but it remains in vitro.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2015 Oncology Reports paper found that widdrol inhibited HUVEC proliferation, migration, and tube formation and reduced tumor growth and blood-vessel formation in colon tumor xenograft mice.
This is the strongest accessible mechanism paper for widdrol, but its evidence tier is still preclinical rather than clinical.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2006 Journal of Agricultural and Food Chemistry paper tested widdrol against Botrytis cinerea and Colletotrichum gloeosporioides and examined fungal biotransformation of the compound.
This supports a constituent-specific antifungal line of evidence, although it is agricultural rather than human therapeutic research.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No isolated-widdrol human safety trial, IFRA monograph, or dedicated dermal sensitization source was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because widdrol occurs as part of cedarwood oils with broader toxicology literature, constituent-specific copy should not overextend oil-level safety conclusions to purified widdrol.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Current functional evidence is mostly cell, fungal, or mouse-model work, so archive language should avoid suggesting proven human anticancer or vascular effects.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
vegfr2_pathway_suppression
A 2015 Oncology Reports paper found that widdrol suppressed phosphorylation of VEGFR2 and downstream AKT, FAK, and eNOS while inhibiting endothelial proliferation, migration, and tube formation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
chk2_p53_p21_cell_cycle_checkpoint_activation
PubMed-indexed mechanistic work reports that widdrol activates a Chk2-p53-Cdc25A-p21-MCM4 signaling cascade in HT29 cells, consistent with G1 checkpoint arrest findings in related studies.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical literature specific to isolated widdrol was verified in this pass.
- Constituent-specific dermal, inhalation, reproductive, and chronic toxicology data remain sparse in the reviewed public sources.
- Much of the functional literature comes from cancer or agricultural lab models and should not be translated into consumer benefit claims.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.